Deregulation of the MiR-193b-KRAS axis contributes to impaired cell growth in pancreatic cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Jin, Xianglan ^a   Sun, Yang ^a   Yang, Haiyan ^a   Li, Ji ^a   Yu, Shuangni ^a   Chang, Xiaoyan ^a   Lu, Zhaohui ^a   Chen, Jie ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

K RAS PROTEIN; MICRORNA; MICRORNA 193B; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; KRAS PROTEIN, HUMAN; MIRN193 MICRORNA, HUMAN; PROTEIN P21;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN FUNCTION; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; 3' UNTRANSLATED REGION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; PANCREATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS P21(RAS); SIGNAL TRANSDUCTION;

EID: 84930681967     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125515     Document Type: Article

References (52)

1. Fang Z, Rajewsky N. The impact of miRNA target sites in coding sequences and in 3'UTRs. PloSone. 2011;6(3):e18067. doi: 10.1371/journal.pone.0018067 PMID: 21445367.
2. Reczko M, Maragkakis M, Alexiou P, Grosse I, Hatzigeorgiou AG. Functional microRNAtargets in protein coding sequences. Bioinformatics. 2012;28(6):771-6. doi: 10.1093/bioinformatics/bts043 PMID: 22285563.
3. Tay Y, Zhang J, Thomson AM, Lim B, Rigoutsos I. MicroRNAsto Nanog, Oct4and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 2008;455(7216):1124-8. doi: 10.1038/nature07299 PMID: 18806776.
4. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAson protein output. Nature. 2008;455(7209):64-71. doi: 10.1038/nature07242 PMID: 18668037.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20. doi: 10.1016/j.cell.2004. 12.035 PMID: 15652477.
6. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of micro-RNAs. Genome research. 2009;19(1):92-105. doi: 10.1101/gr.082701.108 PMID: 18955434.
7. Kloosterman WP, Plasterk RHA. The Diverse Functions of MicroRNAs in Animal Development and Disease. Developmental cell. 2006;11(4):441-50. PMID: 17011485
8. Chang TC, Mendell JT. microRNAs in vertebrate physiology and human disease. Annual review of genomics and human genetics. 2007;8:215-39. doi: 10.1146/annurev. genom.8.080706.092351 PMID: 17506656.
9. Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132(21):4653-62. doi: 10.1242/dev. 02073 PMID: 16224045
10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proceedings of the National Academy of Sciences of the United States of America. 2006;103(7):2257-61. doi: 10.1073/pnas.0510565103 PMID: 16461460.
11. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nature reviews Cancer. 2006;6(4):259-69. doi: 10.1038/nrc1840 PMID: 16557279.
12. American Cancer Society. Cancer Facts & Figures 2012. 2012:19. Available: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2012/.
13. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549-54. PMID: 2453289
14. di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144(6):1220-9. Epub 2013/04/30. doi: S0016-5085 (13) 00191-1 [pii] 10.1053/j.gastro.2013.01.071. PMID: 23622131. doi: 10.1053/j.gastro.2013.01.071
15. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proceedings of the National Academy of Sciences of the United States of America. 2004;101(9):2999-3004. doi: 10.1073/pnas.0307323101 PMID: 14973191
16. Loukopoulos P, Shibata T, Katoh H, Kokubu A, Sakamoto M, Yamazaki K, et al. Genome-wide array-based comparative genomic hybridization analysis of pancreatic adenocarcinoma: identification of genetic indicators that predict patient outcome. Cancer science. 2007;98(3):392-400. doi: 10.1111/j. 1349-7006.2007.00395.x PMID: 17233815.
17. Kowalski J, Morsberger LA, Blackford A, Hawkins A, Yeo CJ, Hruban RH, et al. Chromosomal abnormalities of adenocarcinoma of the pancreas: identifying early and late changes. Cancer genetics and cytogenetics. 2007;178(1):26-35. doi: 10.1016/j.cancergencyto.2007.06.004 PMID: 17889705.
18. Chen J, Feilotter HE, Pare GC, Zhang X, Pemberton JG, Garady C, et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. The American journal of pathology. 2010;176(5):2520-9. doi: 10.2353/ajpath.2010.091061 PMID: 20304954.
19. Xu C, Liu S, Fu H, Li S, Tie Y, Zhu J, et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. European journal of cancer. 2010;46(15):2828-36. doi: 10.1016/j.ejca.2010.06.127 PMID: 20655737.
20. Wu W, Lin Z, Zhuang Z, Liang X. Expression profile of mammalian microRNAs in endometrioid adenocarcinoma. European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation. 2009;18(1):50-5. doi: 10.1097/CEJ.0b013e328305a07a PMID: 19077565.
21. Ikeda Y, Tanji E, Makino N, Kawata S, Furukawa T. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res. 2012;10(2):259-69. Epub 2011/12/23. doi: 1541-7786. MCR-11-0035 [pii] 10.1158/1541-7786. MCR-11-0035. PMID: 22188669. doi: 10.1158/1541-7786. MCR-11-0035
22. Wang C, Sun Y, Wu H, Zhao D, Chen J. Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers. Histopathology. 2014;64(4):567-76. doi: 10. 1111/his.12283 PMID: 24102952.
23. Sohn D, Budach W, Janicke RU. Caspase-2is required for DNA damage-induced expression of the CDK inhibitor p21 (WAF1/CIP1). Cell Death Differ. 2011;18(10):1664-74. Epub 2011/04/09. doi: cdd201134 [pii] 10.1038/cdd.2011.34. PMID: 21475302. doi: 10.1038/cdd.2011.34
24. Lanuti P, Marchisio M, Cantilena S, Paludi M, Bascelli A, Gaspari AR, et al. A flow cytometry procedure for simultaneous characterization of cell DNA content and expression of intracellular protein kinase C-zeta. Journal of immunological methods. 2006;315(1-2):37-48. doi: 10.1016/j.jim.2006.06.015 PMID: 16945385.
25. Zhao WG, Yu SN, Lu ZH, Ma YH, Gu YM, Chen J. The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis. 2010;31(10):1726-33. doi: 10.1093/carcin/bgq160 PMID: 20675343.
26. Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. The American journal of pathology. 2007;171(1):263-73. doi: 10.2353/ajpath.2007.061176 PMID: 17591971.
27. Parsa I, Longnecker DS, Scarpelli DG, Pour P, Reddy JK, Lefkowitz M. Ductal metaplasia of human exocrine pancreas and its association with carcinoma. Cancer research. 1985;45(3):1285-90. PMID: 2982487.
28. Kopp JL, von FiguraG, Mayes E, Liu FF, Dubois CL, Morris JPt, et al. Identification of Sox9-dependent acinar-to-ductal reprogramming as the principal mechanism for initiation of pancreatic ductal adenocarcinoma. Cancer cell. 2012;22(6):737-50. doi: 10.1016/j.ccr.2012.10.025 PMID: 23201164.
29. Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology. 1995;109(1):247-51. PMID: 7797022.
30. Rooman I, Real FX. Pancreatic ductal adenocarcinoma and acinar cells: a matter of differentiation and development? Gut. 2012;61(3):449-58. doi: 10.1136/gut.2010.235804 PMID: 21730103.
31. Ji B, Tsou L, Wang H, Gaiser S, Chang DZ, Daniluk J, et al. Ras activity levels control the development of pancreatic diseases. Gastroenterology. 2009;137(3):1072-82, 82 e1-6. doi: 10.1053/j.gastro.2009. 05.052 PMID: 19501586.
32. Logsdon CD, Ji B. Ras activity in acinar cells links chronic pancreatitis and pancreatic cancer. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association. 2009;7(11 Suppl):S40-3. doi: 10.1016/j.cgh.2009.07.040 PMID: 19896097.
33. Guerra C, Schuhmacher AJ, Canamero M, Grippo PJ, Verdaguer L, Perez-Gallego L, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer cell. 2007;11(3):291-302. doi: 10.1016/j.ccr.2007.01.012 PMID: 17349585.
34. Seton-Rogers S. Tumorigenesis: Pushing pancreatic cancer to take off. Nature reviews Cancer. 2012;12(11):739. doi: 10.1038/nrc3383 PMID: 23037449.
35. Collins MA, Yan W, Sebolt-Leopold JS, Pascadi Magliano M. MAPK signaling is required for dediffer-entiation of acinar cells and development of pancreatic intraepithelial neoplasia in mice. Gastroenterology. 2014;146(3):822-34 e7. doi: 10.1053/j.gastro.2013.11.052 PMID: 24315826.
36. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. The Journal of clinical investigation. 2012;122(2):639-53. doi: 10.1172/JCI59227 PMID: 22232209.
37. Mazzon E, Impellizzeri D, Di Paola R, Paterniti I, Esposito E, Cappellani A, et al. Effects of mitogen-activated protein kinase signaling pathway inhibition on the development of cerulein-induced acute pancreatitis in mice. Pancreas. 2012;41(4):560-70. doi: 10.1097/MPA.0b013e31823acd56 PMID: 22228051.
38. Kent OA, Chivukula RR, Mullendore M, Wentzel EA, Feldmann G, Lee KH, et al. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes & development. 2010;24(24):2754-9. doi: 10.1101/gad.1950610 PMID: 21159816.
39. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. The Journal of clinical investigation. 2012;122(4):1519-28. doi: 10.1172/JCI59743 PMID: 22406536.
40. Collins MA, Pasca di Magliano M. Kras as a key oncogene and therapeutic target in pancreatic cancer. Frontiers in physiology. 2013;4:407. doi: 10.3389/fphys.2013.00407 PMID: 24478710.
41. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, et al. MicroRNAexpression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297(17):1901-8. Epub 2007/05/03. doi: 297/17/1901 [pii] 10.1001/jama.297.17.1901. PMID: 17473300.
42. Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, et al. MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 2007;26(30):4442-52. Epub 2007/01/24. doi: 1210228 [pii] 10.1038/sj.onc.1210228. PMID: 17237814.
43. Greither T, Grochola LF, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. International journal of cancer Journal international du cancer. 2010;126(1):73-80. doi: 10.1002/ijc.24687 PMID: 19551852.
44. Hu H, Li S, Liu J, Ni B. MicroRNA-193b modulates proliferation, migration, and invasion of non-small cell lung cancer cells. Acta biochimicaetbiophysicaSinica. 2012;44(5):424-30. doi: 10.1093/abbs/gms018 PMID: 22491710.
45. Iliopoulos D, Rotem A, Struhl K. Inhibition of miR-193a expression by Max and RXRalpha activates K-Rasand PLAU to mediate distinct aspects of cellular transformation. Cancer research. 2011;71(15):5144-53. doi: 10.1158/0008-5472. CAN-11-0425 PMID: 21670079.
46. Eser S, Schnieke A, Schneider G, Saur D. Oncogenic KRAS signalling in pancreatic cancer. British journal of cancer. 2014;111(5):817-22. doi: 10.1038/bjc.2014.215 PMID: 24755884.
47. Coleman ML, Marshall CJ, Olson MF. RAS and RHOGTPasesin G1-phase cell-cycle regulation. Nature reviews Molecular cell biology. 2004;5(5):355-66. doi: 10.1038/nrm1365 PMID: 15122349.
48. Ma Y, Yu S, Zhao W, Lu Z, Chen J. miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer letters. 2010;298(2):150-8. doi: 10.1016/j. canlet.2010.06.012 PMID: 20638779.
49. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer research. 2010;70(14):6015-25. doi: 10.1158/0008-5472. CAN-09-4531 PMID: 20610624.
50. Collisson EA, Trejo CL, Silva JM, Gu S, Korkola JE, Heiser LM, et al. A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. Cancer Discovery. 2012;2(8):685-93. doi: 10.1158/2159-8290.cd-11-0347 PMID: 22628411
51. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene. 1999;18(20):3085-97. doi: 10. 1038/sj.onc.1202647 PMID: 10340380.
52. Satoh J, Tabunoki H. Comprehensive analysis of human microRNA target networks. BioData mining. 2011;4:17. doi: 10.1186/1756-0381-4-17 PMID: 21682903.